Chronos Therapeutics, a privately-held UK biotech focused on aging diseases, brain and central nervous system (CNS) disorders, has acquired three pre-clinical development programs from a subsidiary of Ireland-headquartered Shire (LSE: SHP).
The programs target CNS diseases and Chronos has acquired all intellectual property, know-how, development and marketing rights for each one on a worldwide basis.
Meanwhile Shire has become a strategic equity investor in Chronos and is eligible for milestone payments on regulatory approval of products relating to the programs, followed by royalties and milestone payments on sales of the products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze